Published in Infect Immun on January 01, 1987
Toxigenic clostridia. Clin Microbiol Rev (1990) 5.40
Clostridial enteric diseases of domestic animals. Clin Microbiol Rev (1996) 4.97
Correlation between plasmid content and infectivity in Borrelia burgdorferi. Proc Natl Acad Sci U S A (2000) 4.81
Molecular genetics and pathogenesis of Clostridium perfringens. Microbiol Rev (1991) 3.81
Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun (1988) 3.11
Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev (2004) 2.60
Characterization of Clostridium perfringens iota-toxin genes and expression in Escherichia coli. Infect Immun (1993) 1.99
The family of bacterial ADP-ribosylating exotoxins. Clin Microbiol Rev (1995) 1.73
Exoenzyme S of Pseudomonas aeruginosa ADP-ribosylates the intermediate filament protein vimentin. Infect Immun (1989) 1.72
ADP-ribosylation of actin by clostridial toxins. J Cell Biol (1989) 1.53
Purification of the Clostridium spiroforme binary toxin and activity of the toxin on HEp-2 cells. Infect Immun (1989) 1.32
Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A (2011) 1.31
The N-terminal part of the enzyme component (C2I) of the binary Clostridium botulinum C2 toxin interacts with the binding component C2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Infect Immun (1998) 1.25
Characterization of the enzymatic component of Clostridium perfringens iota-toxin. J Bacteriol (2000) 1.13
Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases. Infect Immun (1989) 1.09
Binding component of Clostridium perfringens iota-toxin induces endocytosis in Vero cells. Infect Immun (2002) 1.08
Clostridium perfringens iota-toxin: mapping of receptor binding and Ia docking domains on Ib. Infect Immun (2001) 1.02
Clostridium Perfringens Toxins Involved in Mammalian Veterinary Diseases. Open Toxinology J (2010) 1.01
Isolation and characterization of a Clostridium botulinum C2 toxin-resistant cell line: evidence for possible involvement of the cellular C2II receptor in growth regulation. Infect Immun (1995) 0.97
The C terminus of component C2II of Clostridium botulinum C2 toxin is essential for receptor binding. Infect Immun (2000) 0.95
Clostridium and bacillus binary enterotoxins: bad for the bowels, and eukaryotic being. Toxins (Basel) (2014) 0.91
Purification and characterization of alpha-toxin produced by Clostridium novyi type A. Infect Immun (1993) 0.89
Side chain specificity of ADP-ribosylation by a sirtuin. FEBS J (2009) 0.83
Partial characterization of the enzymatic activity associated with the binary toxin (type C2) produced by Clostridium botulinum. Infect Immun (1988) 0.83
Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer. Mol Cancer (2014) 0.78
Inhibition of cytochalasin D-stimulated G-actin ATPase by ADP-ribosylation with Clostridium perfringens iota toxin. Biochem J (1990) 0.78
ADP-ribosylation of Drosophila indirect-flight-muscle actin and arthrin by Clostridium botulinum C2 toxin and Clostridium perfringens iota toxin. Biochem J (1993) 0.76
Inhibiting bacterial toxins by channel blockage. Pathog Dis (2015) 0.75
Clostridium perfringens type E virulence traits involved in gut colonization. PLoS One (2015) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A (1982) 10.36
NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. Proc Natl Acad Sci U S A (1975) 9.15
Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad Sci U S A (1982) 5.68
Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. Proc Natl Acad Sci U S A (1978) 5.49
A new method for the large-scale production of high-titre botulinum formol-toxoid types C and D. J Immunol (1950) 5.19
ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase. Proc Natl Acad Sci U S A (1978) 4.85
ADP-ribosylation. Annu Rev Biochem (1985) 3.30
Botulinum C2 toxin ADP-ribosylates actin. Nature (1986) 3.16
Purification and characterization of two components of botulinum C2 toxin. Infect Immun (1980) 2.74
Adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis by diphtheria toxin. J Biol Chem (1971) 2.23
Purification of cholera toxin and its subunits: new methods of preparation and the use of hypertoxinogenic mutants. Infect Immun (1978) 2.16
Activation of adenylate cyclase by heat-labile Escherichia coli enterotoxin. Evidence for ADP-ribosyltransferase activity similar to that of choleragen. J Clin Invest (1978) 2.07
Clostridium perfringens toxins (type A, B, C, D, E). Pharmacol Ther (1980) 2.02
Evidence that botulinum C2 toxin has two dissimilar components. Infect Immun (1980) 1.77
Crystallization and properties of staphylococcal leukocidin. Biochim Biophys Acta (1980) 1.56
Response of mouse intestinal loop to botulinum C2 toxin: enterotoxic activity induced by cooperation of nonlinked protein components. Infect Immun (1983) 1.41
ADP-ribosylation of nonmuscle actin with component I of C2 toxin. Biochem Biophys Res Commun (1986) 1.38
The mechanism of ADP-ribosylation of elongation factor 2 catalyzed by fragment A from diphtheria toxin. Biochim Biophys Acta (1977) 1.35
Molecular basis for the pharmacological actions of Clostridium botulinum type C2 toxin. J Pharmacol Exp Ther (1984) 1.29
A comparison of the pharmacological properties of Clostridium botulinum type C1 and C2 toxins. J Pharmacol Exp Ther (1982) 1.15
Binding of the two components of C2 toxin to epithelial cells and brush borders of mouse intestine. Infect Immun (1985) 1.15
Anthrax toxin. Pharmacol Ther (1981) 1.11
Lethal and vascular permeability activities of botulinum C2 toxin induced by separate injections of the two toxin components. Infect Immun (1983) 1.11
Clostridial toxins active locally in the gastrointestinal tract. Ciba Found Symp (1985) 0.97
Some properties of the iota-toxin of Clostridium welchii, including its action on capillary permeability. J Pathol Bacteriol (1961) 0.92
Quantification of protein-bound ADP-ribosyl and (ADP-ribosyl)n residues. Methods Enzymol (1984) 0.88
The susceptibility of the mallard duck (Anas platyrhynchos) to Clostridium botulinum C2 toxin. Jpn J Med Sci Biol (1980) 0.85
Current state of the art in the HPLC analyses of free nucleotides, nucleosides, and bases in biological fluids. Adv Chromatogr (1980) 0.85
Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1976) 9.38
Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1973) 9.35
Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol (1977) 8.29
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Development of a micromethod for identification of anaerobic bacteria. Appl Microbiol (1975) 4.58
Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol (1977) 4.09
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Micromethod for identification of anaerobic bacteria: design and operation of apparatus. Appl Microbiol (1975) 3.80
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev (1981) 2.91
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86
Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. Proc Natl Acad Sci U S A (1985) 2.80
Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol (1976) 2.67
Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol (1986) 2.66
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Production by Salmonella typhimurium of 2,3-dihydroxybenzoylserine, and its stimulation of growth in human serum. J Infect Dis (1970) 2.62
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Medium-dependent inhibition of Peptostreptococcus anaerobius by sodium polyanetholsulfonate in blood culture media. J Clin Microbiol (1976) 2.46
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2008) 2.40
Charge-shift probes of membrane potential: a probable electrochromic mechanism for p-aminostyrylpyridinium probes on a hemispherical lipid bilayer. Biophys J (1981) 2.17
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
The enterotoxin of Bacteroides fragilis is a metalloprotease. Infect Immun (1995) 2.06
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Purification and characterization of an enterotoxin from Bacteroides fragilis. Infect Immun (1992) 1.97
Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Resistance of some species of Clostridium to clindamycin. Antimicrob Agents Chemother (1973) 1.81
Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther (1980) 1.79
Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.78
In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother (1975) 1.78
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice. Antimicrob Agents Chemother (1974) 1.71
Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Nationwide data confirms absence of 'July phenomenon' in obstetrics: it's safe to deliver in July. J Perinatol (2007) 1.66
Fibrinolytic activity of oral anaerobic bacteria. Arch Oral Biol (1978) 1.65
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Use of semisolid agar from initiation of pure Bacteroides fragilis infection in mice. Infect Immun (1976) 1.64
Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology (1996) 1.63
Inhibition of Bacteroides fragilis on blood agar plates and reversal of inhibition by added hemin. J Clin Microbiol (1976) 1.63
Beta-Lactamase activity in strains of Bacteroides melaninogenicus and Bacteroides oralis. Antimicrob Agents Chemother (1977) 1.62
Laminarinase (beta-glucanase) activity in Bacteroides from the human colon. Appl Environ Microbiol (1977) 1.61
Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo. Infect Immun (1995) 1.59
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect Immun (1986) 1.57
Requirement of heme for growth of Bacteroides fragilis. Appl Environ Microbiol (1977) 1.53
Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53
Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys (1987) 1.51
Vaspar broth-disk procedure for antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1980) 1.50
Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol (1992) 1.47
The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells. Infect Immun (1997) 1.46
Cytochrome spectrum of an obligate anaerobe, Eubacterium lentum. J Bacteriol (1976) 1.45
Bacteriophages of Bacteroides. Rev Infect Dis (1980) 1.44
Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44
Clostridium perfringens iota toxin: synergism between two proteins. Toxicon (1986) 1.43
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Cost issues surrounding the use of computerized telemedicine for obstetric ultrasonography. Ultrasound Obstet Gynecol (1998) 1.42
Telemetric evaluation of body temperature and physical activity as predictors of mortality in a murine model of staphylococcal enterotoxic shock. Comp Med (2000) 1.40
Cholesterol-reducing bacterium from human feces. Appl Environ Microbiol (1977) 1.40
Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40
Influence of pencillinase production by strains of Bacteroides melaninogenicus and Bacteriodes oralis on pencillin therapy of an experimental mixed anaerobic infection in mice. Arch Oral Biol (1976) 1.39
Cloning and characterization of the gene for the metalloprotease enterotoxin of Bacteroides fragilis. FEMS Microbiol Lett (1997) 1.36
Cellular and molecular actions of binary toxins possessing ADP-ribosyltransferase activity. Toxicon (1991) 1.34
Characterization of cross-reactive proteins detected by Culturette Brand Rapid Latex Test for Clostridium difficile. J Clin Microbiol (1988) 1.34
Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis (1986) 1.34
Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32
The role of calcium in neurohumoral and neurohormonal extrusion processes. J Pharm Pharmacol (1968) 1.29
Molecular basis for the pharmacological actions of Clostridium botulinum type C2 toxin. J Pharmacol Exp Ther (1984) 1.29
Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J Biol Chem (1998) 1.29
Synaptic vesicle movements monitored by fluorescence recovery after photobleaching in nerve terminals stained with FM1-43. J Neurosci (1996) 1.28
Intracerebral hemorrhage in pregnancy: frequency, risk factors, and outcome. Neurology (2006) 1.27
Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents Chemother (1978) 1.26
Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26
Induction of an immune response by oral administration of recombinant botulinum toxin. Infect Immun (1997) 1.21
Isolation of auxotrophs of Bacteroides fragilis. Can J Microbiol (1978) 1.21
High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sci U S A (1992) 1.20
Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect Immun (1999) 1.20
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Bacteriocin production by strains of Bacteroides isolated from human feces and the role of these strains in the bacterial ecology of the colon. Antimicrob Agents Chemother (1977) 1.16
Evidence that deprenyl, A type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem Pharmacol (1978) 1.15
A comparison of the pharmacological properties of Clostridium botulinum type C1 and C2 toxins. J Pharmacol Exp Ther (1982) 1.15
Staphylococcus aureus: the toxic presence of a pathogen extraordinaire. Curr Med Chem (2009) 1.14
Mutagenesis of the Clostridium difficile toxin B gene and effect on cytotoxic activity. Microb Pathog (1994) 1.14
TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1. J Clin Microbiol (1999) 1.13
The fecapentaenes, potent mutagens from human feces. Chem Res Toxicol (1992) 1.11
Role of Clostridium difficile toxins in disease. Gastroenterology (1987) 1.11
Carbohydrate repression of catalase synthesis in Bacteroides fragilis. J Bacteriol (1977) 1.11
Effect of high-fiber and high-oil diets on the fecal flora of swine. Appl Environ Microbiol (1987) 1.10
Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases. Infect Immun (1989) 1.09